Truveta and Alpine Immune Sciences announce partnership to accelerate recruitment to povetacicept clinical trials

Daily updated real-world clinical data from the Truveta community of 28 health systems will speed identification and recruitment of participants to clinical trials of povetacicept, Alpine’s dual B cell cytokine antagonist.

On March 21, 2023, health data and analytics community Truveta and biopharmaceutical company Alpine Immune Sciences announced they are joining forces to utilize real-world clinical data to expedite clinical trial recruitment for povetacicept, Alpine’s dual B cell cytokine antagonist being developed for multiple B cell-mediated autoimmune and inflammatory diseases. The vast reservoir of daily updated US-wide data from Truveta’s 28 health system members will significantly facilitate the identification and recruitment of trial-eligible participants.

Speaking exclusively to The Evidence Base, Terry Myerson, founder and CEO of Truveta, commented: “The lack of timely real-world data has made the process of recruiting patients for cutting-edge therapeutics extremely challenging. This partnership between Truveta and Alpine Immune Sciences ­— in collaboration with our health system members — will accelerate clinical trial recruitment and deliver new therapies faster.”

Truveta comprises 28 health systems that provide 16% of all US healthcare in more than 20,000 clinics and 700 hospitals, from all 50 states. It was formed by leading health systems coming together to address issues of fragmentation and inaccessibility of valuable electronic health record data siloed with individual providers. De-identified real-world data representative of the full diversity of the US — including diagnoses, vital signs, lab tests, clinical notes, and images etc. — is updated daily to Truveta from its members.

“One of the most beneficial things we can do with data is connect patients to clinical trials that offer them new potential treatments and new hope. This new partnership will allow us to accomplish just that,” said Ari Robicsek, Chief Medical Informatics Officer at Providence, a member of Truveta.

Alpine’s Executive Chairman and CEO Mitchell Gold stated: “We are excited to collaborate with Truveta and its health system members to accelerate development of povetacicept across multiple indications. In an environment of increasingly competitive and challenging clinical trials, Truveta will enable Alpine to more quickly identify and recruit study participants who have the potential to benefit most from povetacicept and its unique mechanism of action.”

Povetacicept is a dual B cell cytokine antagonist that has been shown to exhibit greater potency versus multiple comparators in preclinical studies and to be well tolerated in a randomized, placebo-controlled Phase I study of healthy adult volunteers. It is currently in development for multiple B cell and/or autoantibody-related diseases, such as systemic lupus erythematosus. In the new alliance, Alpine and Truveta will work together to rapidly identify and recruit participants for Alpine’s RUBY clinical trial program for povetacicept, including the RUBY-3 study in autoimmune glomerulonephritis and RUBY-4 study in autoimmune cytopenias.